Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Seth Gamradt

Sports Medicine Los Angeles, CA Medical Doctor

NPI 1366642753 CMS profile 1199213

1520 San Pablo St, Suite 2000, Los Angeles, CA 90033

Open in the dashboard

General payments

$566,555

369 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Seth Gamradt of Los Angeles, CA is reported in the CMS Open Payments database as having received $566,555 across 369 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $142,459 71
2024 General $99,336 58
2023 General $105,316 59
2022 General $99,466 46
2021 General $83,690 97
2020 General $34,382 31
2019 General $1,906 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seth Gamradt
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Seth Gamradt were reported at $142,459. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Seth Gamradt Sports Medicine median Middle half National median
2019 $1,906 $1,176 $199–$4,249 $163
2020 $34,382 $708 $96–$2,890 $114
2021 $83,690 $1,213 $152–$3,994 $132
2022 $99,466 $1,230 $159–$3,998 $149
2023 $105,316 $584 $146–$2,836 $160
2024 $99,336 $628 $163–$3,168 $164
2025 $142,459 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Zimmer Biomet Holdings, Inc. $524,568 307 payments
  2. Exactech, Inc. $41,013 36 payments
  3. Arthrex, Inc. $388 15 payments
  4. Stryker Corporation $294 6 payments
  5. Smith+Nephew, Inc. $175 3 payments
  6. Micromed Inc $117 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $263,887 21 payments
  2. Consulting Fee $211,063 143 payments
  3. Education $60,750 19 payments
  4. Travel and Lodging $26,451 107 payments
  5. Food and Beverage $4,404 79 payments
Products named General payments · program years 2019–2025
  1. Comprehensive Glenoid $113,888 8 payments
  2. COMPREHENSIVE $74,275 7 payments
  3. Comprehensive Shoulder System $49,866 49 payments
  4. EQUINOXE $31,910 27 payments
  5. PSI Knee $28,806 2 payments
  6. Alliance $27,269 5 payments
  7. Alliance Glenoid $24,931 2 payments
  8. Comprehensive Anatomic $14,250 11 payments
  9. ROSA $13,748 4 payments
  10. Juggerknotless Soft Anchor $13,138 14 payments
  11. Other $51,392 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$163,797

Of which drugs: $6,198

Medicare patients

454

Average age 74

Services billed

1,517

248 women, 206 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Ischemic heart disease 34%
Diabetes 28%
Depression 24%
Osteoporosis 22%
Cancer 17%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 83 127 $689
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 16 20 $133

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

369 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record